{"classes":[{"categories":[{"measurements":[{"comment":"NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.","groupId":"OG001","spread":"NA","value":"NA"},{"groupId":"OG002","spread":"105.55","value":"381.95"},{"groupId":"OG003","spread":"44.43","value":"1331.11"},{"comment":"NA indicates that geometric coefficient of variation could not be calculated for a single participant.","groupId":"OG004","spread":"NA","value":"4307.00"},{"groupId":"OG005","spread":"113.71","value":"3720.27"},{"groupId":"OG006","spread":"35.70","value":"11420.61"},{"groupId":"OG007","spread":"35.97","value":"28134.46"},{"groupId":"OG008","spread":"75.69","value":"2301.18"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"6"}],"units":"Participants"}],"title":"Day 1, Cycle 1,n=0,1,4,2,1,3,3,2,6"},{"categories":[{"measurements":[{"comment":"NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.","groupId":"OG001","spread":"NA","value":"NA"},{"groupId":"OG003","spread":"28.76","value":"1672.18"},{"comment":"NA indicates that geometric coefficient of variation could not be calculated for a single participant.","groupId":"OG004","spread":"NA","value":"7259.00"},{"groupId":"OG005","spread":"104.56","value":"9510.04"},{"groupId":"OG006","spread":"46.82","value":"12791.83"},{"groupId":"OG007","spread":"6.21","value":"12719.77"},{"groupId":"OG008","spread":"123.56","value":"2643.94"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"5"}],"units":"Participants"}],"title":"Day 1, Cycle 2,n=0,1,0,2,1,2,2,2,5"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"}],"units":"Participants"}],"title":"Day 1, Cycle 4,n=0,0,0,0,0,0,0,0,0"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"6"}],"units":"Participants"}],"description":"Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable. NA indicates that geometric coefficient of variation could not be calculated for a single participant.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).","id":"OG000","title":"Part 1: GSK2857916 0.03 mg/kg"},{"description":"Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).","id":"OG001","title":"Part 1: GSK2857916 0.06 mg/kg"},{"description":"Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).","id":"OG002","title":"Part 1: GSK2857916 0.12 mg/kg"},{"description":"Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).","id":"OG003","title":"Part 1: GSK2857916 0.24 mg/kg"},{"description":"Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).","id":"OG004","title":"Part 1: GSK2857916 0.48 mg/kg"},{"description":"Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).","id":"OG005","title":"Part 1: GSK2857916 0.96 mg/kg"},{"description":"Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).","id":"OG006","title":"Part 1: GSK2857916 1.92 mg/kg"},{"description":"Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).","id":"OG007","title":"Part 1: GSK2857916 3.40 mg/kg"},{"description":"Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).","id":"OG008","title":"Part 1: GSK2857916 4.60 mg/kg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK Part 1 Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).","reportingStatus":"POSTED","timeFrame":"Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1), Pre-dose and EOI of Day 1 (Cycle 2 and Cycle 4)","title":"Trough Plasma Concentration (Ctrough) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1","type":"SECONDARY","unitOfMeasure":"Nanograms per milliliter"}